Clinical trial NCT06055829: The Adjustment of Doses in Diabetes Mellitus Type I
Official title: The Adjustment of Doses in Diabetes Mellitus Can Lead to Fluctuation of Glucose Level in Type I
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 1
Keywords: Diabetes mellitus, Insulin injection, Patients training
Lead sponsor: Liwa College
Sponsor class: OTHER
First posted: 2023-09-28
Enrollment: 1
Sex: FEMALE
Minimum age (years): 41
Maximum age (years): 41
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study was carried out in a diabetic patient who was starting a new approach for treatment. Previously the patient was treated with Novo-mix insulin injection twice per day, the physician decided to change the treatment strategy to be with three doses of novo-rapid insulin injections per day plus one injection of Lantus SoloStar at dinner.

Brief summary: The study was carried out in a diabetic patient who was starting a new approach for treatment. Previously the patient was treated with Novo-mix insulin injection twice per day, the physician decided to change the treatment strategy to be with three doses of novo-rapid insulin injections per day plus one injection of Lantus SoloStar in dinner. For two weeks we were monitoring the blood glucose level by the FreeStyle Libre sensor. Moreover, the right statistical technique was used for data analysis.

Detailed description: In this study a diabetic patient is starting a new approach to treatment. Previously, the patient received Novo-Mix insulin injection twice per day (48 Units in breakfast \& 28 Units in dinner). Moreover, the physician decided to change the treatment strategy to be with Novo-Rapid insulin injection three times per day (36 Units in breakfast, 36 Units in lunch \& 50 Units in dinner) plus one time injection of Lantus SoloStar (50 Units) in dinner. Thus, for monitoring blood glucose level, we are using the FreeStyle Libre-Link. Moreover. Moreover, FreeStyle Libre sensor continuously measures glucose every time when scanned by the mobile and saves the glucose data in the library. Moreover, scanning the FreeStyle Libre sensor with a phone or the reader measures the glucose levels from the interstitial fluid, a thin layer of fluid that surrounds the cells of the tissues in the skin of the patient \[4\]. The Scan was done every 1-2 hours for a full glycemic profile.

Eligibility criteria: Inclusion Criteria:

* Diabetic patient

Exclusion Criteria:

* Normal patient

Primary outcomes:
measure: Glucose level
timeFrame: Two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Abu Dhabi
country: United Arab Emirates
facility: Hisham Ibrahim
Study officials:
References:
citation: Shi XY, Zhang K, Zhang L. [Type 1 diabetes millitus following short-term recombinant interferon therapy in patient with chronic hepatitis C]. Zhonghua Nei Ke Za Zhi. 2018 Jul 1;57(7):524-525. doi: 10.3760/cma.j.issn.0578-1426.2018.07.012. No abstract available. Chinese.
citation: Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14.